IPL 423323
Alternative Names: IPL 400; IPL 4323; SortacLatest Information Update: 26 Feb 2003
Price :
$50 *
At a glance
- Originator Inflazyme Pharmaceuticals
- Class
- Mechanism of Action Phosphotransferase stimulants; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis; Transplant rejection
Most Recent Events
- 26 Feb 2003 No development reported - Preclinical for Psoriasis in Canada (unspecified route)
- 26 Feb 2003 No development reported - Preclinical for Transplant rejection in Canada (unspecified route)
- 07 Feb 2000 IPL 423323 is available for licensing (http://www.inflazyme.com)